tailieunhanh - A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells

Zinc as a biomarker can be used to diagnose the early stage prostate cancer, while ZIP1 protein, a zinc transporter is significantly down-regulated in prostate cancer cells. This behavior leads to the apparent alteration of the enrichment ability for zinc between early prostate cancer tissues and healthy tissues. This difference inspires us to develop a novel Zn2+ sensor that applies to the clinic diagnosis of early prostate cancer. We designed a tetrapeptide sensor H2L (Dansyl-Gly-Pro-Trp-Gly-NH2) according to the photo-induced electron transfer principle (PET), and it performed adequately in Zn2+ imaging of prostate cell lines. Based on the assessment of Zn2+ enrichment ability, there was distinctly lower Zn2+ concentrate in prostate cancer cell lines than healthy prostate epithelial cells. Furthermore, H2L displayed high sensitivity with a detection limit as low as nM, and high specificity for Zn2+ detection. Also the low toxicity and the superior cell permeability of H2L made the imaging of Zn2+ ions detection safe and rapid. We expect that H2L to be a powerful tool for early diagnosis of prostate cancer and a good indicator for the precise resection of cancer tissue during surgery. | A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2 in healthy versus cancerous cells

• Y khoa - Dược
• Fluorescent sensor
• Prostate cancer cells
• Imaging diagnosis
• Healthy versus cancerous cells
• Early diagnosis
• Prostate cancer based
• BMC Cancer
• Quality of cancer care
• Prostate cancer
• Quality indicators
• Cancer registry
• Population based study
• Regulatory T cell
• Platinum based chemotherapy
• Multiple cancer cell lines
• Anti prostate cancer
• Primary care
• Secondary care
• General practitioner
• Randomized controlled trial
• Castrate resistant prostate cancer
• Network based analysis
• Protein protein interaction
• Hormone refractory
• Steroid hormone receptors
• Radical prostatectomy
• Salvage radiotherapy
• Recently published data
• Prostate specific membrane antigen
• Metastasis directed treatment
• Physical activity
• Quality of life
• Treatment toxicity
• Androgen deprivation therapy
• Internet based intervention
• Breast cancer survivors
• Prostate cancer survivors
• Breast cancer
• Group intervention
• Self care
• Population based survival rate
• Kurdistan province
• Prognostic factors
• Health care systems
• Urologic Malignancies
• Vaccine and Cancer
• Genitourinary Tumors
• Prostate Cancer Immunotherapy
• Based Vaccine Candidate
• Analyzing diagnostic
• Disease progression
• Family history
• Modelling overall survival
• Cancer specific
• BMC Chemistry
• Protein biomarker
• Body fluids
• Remarkable physical
• Graphene based biosensors
• Chronic inflammatory disease
• Autoimmune disease
• Anti inflammatory medication
• In silico model
• Radium 223
• Prostate cancer bone metastasis
• Tumor growth
• Therapy response
• Therapy optimization
• Sleep disorders
• Cohort study
• Disrupted sleep rhythms
• Type 2 diabetes mellitus
• Antidiabetic medication
• Prostate cancer risk
• Antidiabetic medications
• Anti androgens
• Fracture risk
• E intervention
• Web based
• Psychosocial interventions
• Psychosocial treatment
• Significant morbidity and mortality
• Circadian disruption
• Anti inflammatory drugs
• DNA methylation
• Progression biomarkers
• Watchful waiting
• Docetaxel resistance prostate cancer
• Single cell RNA sequencing
• PANDA method
• Transcription factor network analysis
• Health policy
• Functional outcomes
• Socioeconomic disadvantage